HingeW Peptide Inhibitors for c-Jun Functional Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing c-Jun antagonists face challenges in achieving functional antagonism and desirable pharmacokinetic properties for therapeutic use.
Innovation Solution
The development of novel peptide inhibitors, such as HingeW, which bind to c-Jun and antagonize its DNA-binding function, using a library-based approach and iterative truncations to enhance drug-like characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If longer peptides targeting the full c-Jun bZIP domain are used, then functional antagonism is achieved by simultaneously blocking DNA binding and LZ dimerisation, but peptide length and complexity increase
Solution Approach 1:
The patent extracts and optimizes specific critical regions from the full-length c-Jun bZIP domain peptide. Instead of using the complete long peptide, the invention identifies and utilizes shorter peptide sequences that specifically target the DNA-binding interface, achieving functional antagonism with reduced length and complexity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent segments the c-Jun bZIP domain into functionally distinct regions: the leucine zipper domain responsible for dimerisation and the DNA-binding domain responsible for transcriptional activation. By designing peptides that specifically target these segmented regions, the invention achieves selective antagonism with optimized peptide length, blocking either dimerisation or DNA binding without requiring the full-length peptide.
2Strength
If peptides are designed to target the leucine zipper binding interface, then high affinity binding is achieved, but functional antagonism cannot be predicted as the DBD remains unbound and capable of binding TRE DNA
Solution Approach 1:
The patent introduces a peptide design that acts as an intermediary by simultaneously engaging both the leucine zipper domain and the DNA-binding domain of c-Jun. This dual-targeting peptide serves as a mediator that connects the dimerisation interface and the transcriptional activation interface, ensuring that high affinity binding at the LZ interface translates into reliable functional antagonism by also preventing DBD-TRE DNA interaction.
Solution Approach 2:
The patent merges the targeting capabilities of separate LZ-domain peptides and DBD-domain peptides into a single unified peptide sequence. This combined peptide simultaneously interacts with both the leucine zipper and DNA-binding domains of c-Jun, ensuring that high binding affinity is converted into reliable functional antagonism by blocking both dimerisation and DNA binding activities in one integrated molecule.
3Adaptability or versatility
If rational peptide design targets the c-Jun DBD, then specificity is improved, but potency is reduced compared to LZ antagonists
Solution Approach 1:
The patent combines the high specificity characteristics of DBD-targeting peptides with the high potency characteristics of LZ-targeting peptides into a single unified peptide sequence. This merged design allows the peptide to simultaneously engage both the leucine zipper domain (providing potency through high affinity binding) and the DNA-binding domain (providing specificity through selective interaction), thereby achieving both high potency and high specificity that neither approach could achieve alone.
Solution Approach 2:
The patent creates a composite peptide structure that integrates functional elements from both LZ-domain antagonists and DBD-domain antagonists. This composite peptide incorporates sequence motifs that target the leucine zipper interface alongside motifs that target the DNA-binding domain, creating a multifunctional molecule that achieves both the potency of LZ antagonists and the specificity of DBD antagonists in a single therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HingeW peptides demonstrate high affinity for c-Jun, effectively antagonize c-Jun/TRE DNA interaction, and exhibit improved stability and membrane permeability, making them potential therapeutic candidates.
Implementation Method 1
TF function relies on protein-protein interactions (PPIs) and protein-DNA interactions which form many points of contact over their large surfaces
Data Source
AI summary
c-Jun antagonists are described. Compositions comprising these c-Jun antagonists, as well as methods, including therapeutic methods and therapeutic uses of the c-Jun antagonist are also described.